Clinical Research Library

Our clinical protocols are rooted in evidence-based medicine. We utilize peer-reviewed data to guide our patient selection and treatment strategies, focusing on the safety, functional outcomes, and biological mechanisms of orthobiologic therapies.

Bone Marrow Aspirate Concentrate (BMAC) Clinical Research

Sentinel & Long-Term Studies

Hernigou et al. (2021) — Subchondral vs. Intra-Articular BMAC: 15-Year Randomized Study in Knee OA

This landmark 15-year randomized study treated 60 patients with arthritis in both knees — one knee received stem cells injected directly into the bone beneath the cartilage (subchondral), while the other received the same cells injected into the joint; at 15 years, only 20% of the subchondral-treated knees needed a knee replacement compared to 70% of the joint-injected knees. This is the longest follow-up study of its kind and strongly suggests that delivering stem cells into the bone is far more effective than injecting them into the joint alone. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32617651

Hernigou et al. (2021) — Subchondral BMAC vs. Contralateral Knee Replacement: 15-Year Follow-Up in 140 Patients

In this large study of 140 elderly patients (average age 75) scheduled for bilateral knee replacement, one knee received the replacement while the other received stem cells injected into the subchondral bone instead; at 15 years, only 18% of the stem cell-treated knees eventually needed a knee replacement — a rate comparable to the revision rate of the knee replacements themselves. The study showed that bone marrow lesions (swelling in the bone) larger than 3 cm that did not shrink after treatment were the strongest predictor of eventually needing surgery. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32322943

Hernigou et al. (2018) — Subchondral BMAC vs. Knee Replacement in Young Patients with Osteonecrosis This randomized trial studied 30 young patients (average age 28) with severe knee arthritis caused by steroid-related bone death (osteonecrosis) in both knees — one knee received a knee replacement and the other received subchondral stem cell injection; at 12 years, only 1 stem cell-treated knee needed further surgery compared to 6 knee replacements that required revision, and 21 of 30 patients preferred the stem cell-treated knee. The study demonstrated that subchondral BMAC had fewer complications, faster recovery, and comparable functional outcomes to knee replacement in this challenging young patient population. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/29589086

Pearl et al. (2023) — BMAC Chondroplasty with Intraosseous Injection to Delay Knee Replacement

- In this study of veterans with knee arthritis, BMAC was applied both into the joint and into the bone during a minor surgical procedure; only 22% of patients required any further intervention within 2 years, and only one patient requested a knee replacement. These results suggest that BMAC chondroplasty may help delay or avoid the need for knee replacement surgery. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37994424

Anz et al. (2022) — BMAC vs. PRP Randomized Trial for Knee OA

This randomized trial of 90 patients found that a single BMAC injection improved knee pain and function for up to 2 years, performing equally well as platelet-rich plasma (PRP). Both treatments provided meaningful and sustained relief, with improvements plateauing at 3 months and lasting through 24 months.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35289231

Keeling et al. (2022) — Systematic Review of BMAC for Knee OA

This review of 8 studies and 299 knees found that BMAC injections significantly improved pain and function in over 94% of measured outcomes, though BMAC was not proven superior to other biologic treatments like PRP. The findings support BMAC as an effective option for knee arthritis symptom relief.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34236913

Belk et al. (2023) — Meta-Analysis: PRP/BMAC vs. Hyaluronic Acid for Knee OA

This large meta-analysis of 27 Level I studies found that patients receiving BMAC or PRP injections experienced significantly better pain relief and function compared to those receiving hyaluronic acid (gel) injections. BMAC and PRP performed similarly to each other, but both outperformed traditional gel injections.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36913992

Pabinger et al. (2024) — 4-Year Results of BMAC for Severe Knee OA

In patients with severe knee arthritis (Kellgren-Lawrence grade III–IV), a single BMAC injection led to significant improvements in pain, function, and walking distance sustained over 4 years, with a 95% success rate and no patients requiring knee replacement. This is one of the longest follow-up studies for BMAC in advanced arthritis.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38302491

Manchikanti et al. (2020) — ASIPP Evidence-Based Position Statement on BMAC

This comprehensive review by the American Society of Interventional Pain Physicians found the strongest evidence (Level II) for BMAC in knee osteoarthritis, with emerging evidence across multiple musculoskeletal conditions, and confirmed strong evidence for the safety of BMAC when performed by trained physicians. The statement supports BMAC as meeting FDA criteria for minimal manipulation and homologous use in musculoskeletal care.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32214287

TENDINOPATHY

Pascual-Garrido et al. (2012) — 5-Year Follow-Up of Bone Marrow Stem Cells for Patellar Tendinopathy

This early study treated patients with chronic patellar (kneecap) tendon pain using bone marrow-derived cells and found significant improvements in pain and function that were maintained for 5 years. It was one of the first studies to demonstrate long-term durability of stem cell treatment for tendon problems.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/22220180

Rodas et al. (2021) — Bone Marrow Stem Cells vs. PRP for Patellar Tendinopathy

This double-blind randomized trial found that both bone marrow stem cells and PRP reduced pain and improved activity levels in athletes with chronic patellar tendon problems, but patients receiving stem cells showed significantly greater improvement in tendon structure on MRI and ultrasound. The study suggests stem cells may promote better tendon healing compared to PRP alone.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33783227

Thueakthong et al. (2021) — BMAC for Recalcitrant Achilles Tendinopathy

Patients with chronic Achilles tendon pain that had not responded to other treatments received a BMAC injection and experienced significant pain reduction that continued to improve over 48 weeks, with no complications. This study suggests BMAC may be a safe and effective option for stubborn Achilles tendon problems that have failed other treatments.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34254148

PARTIAL ROTATOR CUFF TEARS — BMAC & PRP

Kim et al. (2017) — Effects of BMAC-PRP on Tendon-Derived Stem Cells and Rotator Cuff Tendon Tear

This study investigated the effects of ultrasound-guided BMAC-PRP injections at the tear site in patients with partial rotator cuff tears and found that ASES scores improved significantly from 39.4 at baseline to 71.8 at 3 months (p < 0.01), with pain scores also decreasing significantly, while MRI showed visible reduction in tear size at 3 months. The laboratory component of the study also demonstrated that BMAC-PRP enhanced stem cell proliferation and migration while preventing abnormal cell differentiation, providing a mechanistic basis for the clinical improvements observed.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/28105983

LONG-TERM SAFETY & EFFICACY — PARTIAL ROTATOR CUFF TEARS

Centeno et al. (2024) — Percutaneous BMC and Platelet Products vs. Exercise Therapy for Rotator Cuff Tears: 2-Year Follow-Up

This randomized controlled trial found that patients with partial or full-thickness rotator cuff tears who received percutaneous BMAC and platelet product injections had significantly greater improvements in pain, function (DASH), and overall satisfaction compared to exercise therapy alone, with benefits sustained through 2 years and no serious adverse events. A majority of treated patients (73%) showed MRI evidence of tendon healing, and over 90% achieved clinically meaningful improvement by 12 months.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38762734

PRP Clinical Research

KNEE OSTEOARTHRITIS

Bensa et al. (2025) — Meta-Analysis of 18 RCTs: PRP vs. Placebo for Knee OA (1,995 Patients)

This large meta-analysis of 18 randomized controlled trials found that PRP injections provided clinically meaningful improvements in both pain and function compared to placebo at 1, 3, 6, and 12 months, with pain relief exceeding the threshold patients can actually feel at 3 and 6 months. Importantly, the study found that high-platelet PRP provided superior and longer-lasting results than low-platelet PRP, suggesting that the concentration of platelets in the injection matters for treatment success.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39751394

Jawanda et al. (2024) — Network Meta-Analysis of 48 RCTs: PRP, BMAC, HA, and Corticosteroid for Knee OA (9,338 Knees)

This massive network meta-analysis of 48 randomized trials and over 9,300 knees found that PRP ranked as the most effective injection for both pain relief and functional improvement at 6+ months, outperforming bone marrow concentrate, hyaluronic acid, corticosteroid, and placebo. The study confirmed that corticosteroid injections ranked last among all biologic options, performing no better than placebo at 6 months.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38331363

Singh et al. (2022) — Network Meta-Analysis of RCTs: Relative Efficacy of Knee OA Injections

This network meta-analysis of randomized controlled trials found that PRP had the highest probability of being the most effective injection for both pain and function in knee osteoarthritis at 6+ months, followed by plasma rich in growth factors (PRGF), hyaluronic acid, and corticosteroid — with corticosteroid performing no better than placebo. PRP was the only injection to demonstrate a clinically meaningful difference in function compared to both corticosteroid and placebo.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34403285

Bennell et al. (2021) — RESTORE Trial: PRP vs. Placebo for Knee OA (JAMA, 288 Patients)

This rigorous, double-blind randomized trial published in JAMA found that three weekly injections of leukocyte-poor PRP did not result in a significant difference in knee pain or cartilage volume compared to saline placebo at 12 months in patients with mild-to-moderate knee osteoarthritis. This is one of the highest-quality individual trials and highlights that not all PRP formulations may be equally effective — the study used a low-platelet, leukocyte-poor preparation that subsequent meta-analyses have shown may be less effective than high-platelet formulations.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34812863

Johal et al. (2019) — Largest Meta-Analysis: PRP Across All Orthopedic Conditions (78 RCTs, 5,308 Patients)

This is the largest meta-analysis of PRP in orthopedics, including 78 randomized controlled trials and over 5,300 patients across multiple conditions; it found that PRP reduced pain at 3 months with benefits increasing and becoming clinically significant by 1 year. The strongest evidence for clinically meaningful pain relief was found for lateral epicondylitis (tennis elbow) and knee osteoarthritis.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31136726

Qiao et al. (2023) — Network Meta-Analysis: PRP, PRP+HA, HA, and Corticosteroid for Knee OA (35 RCTs)

This network meta-analysis of 35 randomized trials found that PRP and PRP combined with hyaluronic acid were the most effective treatments for improving both pain and function at 3, 6, and 12 months, and that none of the treatments — including PRP — increased the risk of side effects compared to placebo. The combination of PRP + HA showed particular promise for pain relief, suggesting that combining these two treatments may offer additional benefit.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38037038

HIP OSTEOARTHRITIS

Dallari et al. (2016) — Level I RCT: PRP vs. HA vs. PRP+HA for Hip OA (111 Patients)

This Level I randomized controlled trial of 111 patients found that PRP injections provided significantly better pain relief than both hyaluronic acid and PRP+HA combination at 6 months, with the benefit remaining more stable through 12 months than either comparator. Interestingly, adding hyaluronic acid to PRP did not improve outcomes — PRP alone was the most effective treatment.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/26797697

Lim et al. (2023) — First Systematic Review & Meta-Analysis: PRP for Hip OA (331 Patients)

This first-of-its-kind systematic review of PRP for hip osteoarthritis found that PRP significantly reduced pain compared to baseline, with the greatest effect at 1–2 months, and that a single injection of leukocyte-poor PRP at a dose under 15 mL produced the best results. The study provides early evidence that PRP may help patients with hip arthritis who are too early for hip replacement but not responding to other conservative treatments.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35971803

ROTATOR CUFF — INJECTION FOR TENDINOPATHY & PARTIAL TEARS

Yuwarungsikul et al. (2026) — Meta-Analysis of 10 RCTs: PRP vs. Corticosteroid for Rotator Cuff Tendinopathy

This meta-analysis of 10 randomized controlled trials (591 patients) found that PRP injections provided significantly better shoulder function scores (ASES +10.8 points, Constant-Murley +10.7 points) and pain relief compared to corticosteroid injections at 6 months, with fewer adverse events. While corticosteroid provided faster initial relief, PRP offered more durable improvement, supporting its use as a longer-lasting alternative for rotator cuff tendinopathy.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/42021740

Kwong et al. (2021) — Double-Blind RCT: PRP vs. Corticosteroid for Partial Rotator Cuff Tears (99 Patients)

This double-blind randomized trial of 99 patients found that PRP injection produced significantly greater improvement in pain, shoulder function (ASES), and quality of life (WORC) scores at 3 months compared to corticosteroid injection for partial-thickness rotator cuff tears and tendinopathy. While both treatments improved symptoms, PRP provided superior short-term results, though the difference was not sustained at 12 months.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33127554

ROTATOR CUFF — PRP AUGMENTATION OF SURGICAL REPAIR

Chen et al. (2020) — Meta-Analysis of 18 Level I Studies: PRP for Rotator Cuff Tears (1,116 Patients)

This meta-analysis exclusively of Level I randomized trials found that PRP significantly reduced long-term retear rates by 66% (OR 0.34) in patients undergoing rotator cuff repair, with the benefit seen regardless of whether leukocyte-rich or leukocyte-poor PRP was used. The study also found that PRP was particularly effective in patients with multiple tendon tears, where retear rates were reduced by 72%.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31743037

Dunivan et al. (2026) — Meta-Analysis: LP-PRP Reduces Retear Risk After Rotator Cuff Repair (21 Studies, 1,279 Patients)

This comprehensive meta-analysis found that leukocyte-poor PRP (LP-PRP) augmentation during arthroscopic rotator cuff repair reduced structural retear rates by approximately 46%, with the most consistent benefit in medium-sized tears. An economic analysis showed that LP-PRP may achieve cost neutrality or modest savings by reducing the need for costly revision surgeries.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41759819

Hovland et al. (2025) — Meta-Analysis of 9 RCTs: LP-PRP in Rotator Cuff Repair (743 Patients)

This meta-analysis of 9 randomized controlled trials found that leukocyte-poor PRP reduced retear rates by 46% compared to controls (risk ratio 0.54, p < .00001), with significantly improved pain, ASES, Constant, and UCLA scores — though the clinical outcome improvements did not meet the minimal clinically important difference. The primary benefit of LP-PRP is enhancing structural tendon healing rather than improving symptoms.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/40409437

LATERAL EPICONDYLITIS (TENNIS ELBOW)

Lhee et al. (2025) — RCT: PRP vs. Prolotherapy vs. Shockwave vs. Physiotherapy for Chronic Tennis Elbow (231 Patients, 2-Year Follow-Up)

This large randomized trial of 231 patients found that PRP produced the greatest improvement in arm function (DASH score reduction of 31 points) and highest patient satisfaction at 2 years compared to prolotherapy, shockwave therapy, and physiotherapy alone. PRP and prolotherapy both significantly outperformed shockwave and physiotherapy, supporting their use as effective non-surgical options for chronic tennis elbow that has not responded to initial treatment.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/40815854

Xu et al. (2024) — Meta-Analysis of 11 RCTs: PRP vs. Corticosteroid for Lateral Epicondylitis (730 Patients)

This meta-analysis found that while corticosteroid injections provided faster pain relief in the first 2 months, PRP delivered significantly better long-term pain relief and functional improvement at 6+ months for tennis elbow. The study highlights the classic trade-off: corticosteroid works faster but fades, while PRP takes longer to work but provides more durable results.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38357713

Antunes Júnior et al. (2026) — Meta-Analysis of 6 RCTs: PRP vs. Placebo for Lateral Epicondylitis (355 Patients)

This recent meta-analysis comparing PRP specifically to placebo (rather than corticosteroid) found no significant benefit of PRP over placebo for pain or function at any time point (4, 8–12, or 24–26 weeks) in patients with tennis elbow. This contrasting finding highlights that while PRP may outperform corticosteroid long-term, its superiority over placebo alone remains unproven for this condition.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41508659

PLANTAR FASCIITIS

Peerbooms et al. (2019) — Level I Double-Blind Multicenter RCT: PRP vs. Corticosteroid for Plantar Fasciitis (115 Patients)

This double-blind multicenter randomized trial found that while corticosteroid injection provided faster initial pain relief, PRP produced significantly greater pain reduction and functional improvement at 1 year, with 84% of PRP patients achieving at least 25% improvement compared to only 56% in the corticosteroid group. The study demonstrates that PRP provides more durable relief for chronic plantar fasciitis than corticosteroid injection.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31603721

Hohmann et al. (2021) — Meta-Analysis of 15 RCTs: PRP vs. Corticosteroid for Plantar Fasciitis

This meta-analysis of 15 randomized trials found that PRP was superior to corticosteroid for pain control starting at 3 months and lasting through 12 months, with no advantage for corticosteroid even in the short term. The study supports PRP as a first-line injection option for chronic plantar fasciitis, though the authors note that low study quality warrants cautious interpretation.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32822236

GLUTEAL TENDINOPATHY / GREATER TROCHANTERIC PAIN SYNDROME

Fitzpatrick et al. (2019) — Level I Double-Blind RCT: PRP vs. Corticosteroid for Gluteal Tendinopathy (80 Patients, 2-Year Follow-Up)

This double-blind randomized trial found that a single PRP injection produced significantly greater and more sustained improvement in hip pain and function than corticosteroid injection, with benefits continuing to improve through 2 years (baseline mHHS 53.8 → 82.6 at 2 years). Notably, 27 patients who failed corticosteroid treatment were crossed over to PRP and experienced significant improvement, further supporting PRP’s superiority for this condition.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/30840831

Atchia et al. (2025) — Double-Blind RCT: PRP vs. Placebo for Greater Trochanteric Pain Syndrome (79 Patients)

This rigorous double-blind trial found no significant difference between PRP and placebo injection for greater trochanteric pain syndrome at any follow-up point through 12 months, with both groups showing improvement from baseline. This contrasting result to the Fitzpatrick trial highlights that PRP’s benefit for this condition may depend on the specific formulation and injection technique used.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39804899

ACHILLES TENDINOPATHY

Kearney et al. (2021) — JAMA Multicenter RCT: PRP vs. Sham Injection for Achilles Tendinopathy (240 Patients)

This large, multicenter randomized trial published in JAMA found that a single PRP injection was no more effective than a sham (dry needle) injection for chronic midportion Achilles tendinopathy at 6 months, with both groups showing similar modest improvement. This is one of the highest-quality trials in the field and does not support the use of PRP for this specific condition.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34228062

Barreto et al. (2025) — Meta-Analysis of 6 RCTs: PRP for Achilles Tendinopathy (422 Patients)

This meta-analysis confirmed that PRP does not improve pain or function compared to placebo at 3, 6, or 12 months for Achilles tendinopathy, and noted that publication bias may have inflated the apparent benefits seen in earlier studies. The authors conclude that PRP should not be used for Achilles tendinopathy until future high-quality trials demonstrate a clear benefit.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39745256

PATELLAR TENDINOPATHY (JUMPER’S KNEE)

Andriolo et al. (2019) — Systematic Review & Meta-Analysis of 70 Studies: Nonsurgical Treatments for Patellar Tendinopathy (2,530 Patients)

This comprehensive review of 2,530 patients found that while eccentric exercises provided the best short-term results, multiple PRP injections produced the best long-term outcomes (≥6 months) for patellar tendinopathy, outperforming shockwave therapy and exercise alone. The study supports a treatment approach of starting with exercise therapy and considering multiple PRP injections for patients who do not improve.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/29601207

Scott et al. (2019) — Level I RCT: LR-PRP vs. LP-PRP vs. Saline for Patellar Tendinopathy (57 Patients)

This Level I randomized trial found that neither leukocyte-rich nor leukocyte-poor PRP was more effective than saline injection when combined with a structured rehabilitation program for patellar tendinopathy at any time point through 12 months. The study suggests that the exercise rehabilitation program itself may be the primary driver of improvement, and a single PRP injection may not add meaningful benefit for this condition.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31038979

MENISCAL TEARS

Sánchez et al. (2023) — Largest PRP Study for Meniscal Tears: Intrameniscal + Intra-Articular PRP (392 Patients)

This large study of 392 patients with meniscal tears found that a combination of PRP injected directly into the torn meniscus and into the joint achieved a remarkable 90.3% survival rate (meaning only 10% eventually needed surgery) with a mean survival time of over 4.5 years. All patient-reported outcome scores improved significantly, and the treatment was most effective for horizontal tears and less effective when cartilage damage was also present.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37302993

Xie et al. (2022) — Meta-Analysis of 8 RCTs: PRP Augmentation of Meniscal Repair Surgery (431 Patients)

This meta-analysis found that adding PRP during meniscal repair surgery significantly improved pain scores and knee function (Lysholm score) compared to surgery alone, with no serious adverse events reported. While the healing rate trended toward improvement with PRP, it did not reach statistical significance, suggesting PRP enhances the recovery experience even if its effect on structural healing needs further study.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35984172

SAFETY

Nakagawa et al. (2026) — Safety Meta-Analysis of 32 RCTs: PRP Adverse Events for Knee OA (1,268 PRP-Treated Knees)

This safety-focused meta-analysis of 32 randomized trials found that PRP injections caused only mild, temporary side effects — most commonly mild knee pain and swelling (10.6%) that resolved without treatment — and no serious adverse events were reported in any study. Leukocyte-poor PRP had a safety profile identical to hyaluronic acid, while leukocyte-rich PRP caused slightly more temporary swelling, confirming PRP’s excellent overall safety.

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/42101047

MFAT Clinical Research

KNEE OSTEOARTHRITIS

Richter et al. (2025) — Randomized Controlled Trial: MFAT vs. Corticosteroid vs. Saline for Knee OA

This randomized controlled trial of 75 patients found that a single MFAT injection provided significantly better and longer-lasting pain relief than both corticosteroid and saline placebo injections, with improvements sustained through 1 year — while corticosteroid benefits faded after just 6 weeks. The study suggests MFAT may be a viable alternative for patients with knee arthritis who fall into the “treatment gap” between conservative care and surgery.

[1]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39243998

Zaffagnini et al. (2022) — Level I RCT: MFAT vs. PRP for Knee OA at 2-Year Follow-Up

This Level I randomized trial of 118 patients found that a single MFAT injection provided clinically significant improvements in pain and function lasting up to 2 years, performing comparably to PRP with no disease progression on MRI. Notably, patients with moderate-to-severe arthritis who received MFAT were significantly more likely to achieve a meaningful clinical improvement than those who received PRP (75% vs. 35%).

[2]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35984721

Gobbi et al. (2021) — Multi-Center International Study: MFAT in Elderly Patients with Knee OA

This multi-center international study of 75 elderly patients (average age 70) with KL grade 2–4 knee arthritis found that a single MFAT injection led to significant improvements in pain, function, and quality of life sustained through 2 years, with an 88% success rate even in patients with advanced disease. The study provides evidence that MFAT is a safe and effective option for older patients who may not be ideal surgical candidates.

[3]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33649891

Ulivi et al. (2023) — RCT: MFAT + Arthroscopic Debridement vs. Debridement Alone for Knee OA

This randomized trial of 78 patients with severe knee arthritis (KL grade 3–4) found that adding MFAT to arthroscopic debridement significantly improved functional scores and MRI cartilage appearance compared to debridement alone, with benefits lasting over 2 years. The study supports the use of MFAT as an add-on treatment during knee arthroscopy to enhance outcomes in advanced arthritis.

[4]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36040510

De Groote et al. (2025) — MFAT for Advanced Knee OA Including KL Grade IV

This longitudinal study of 39 patients with moderate-to-severe knee arthritis (KL grade II–IV) found that a single MFAT injection produced clinically meaningful improvements in all pain and function scores, peaking at 6 months and remaining above baseline at 1 year — including in patients with the most advanced disease. Only minor, self-limiting joint swelling was reported in 18% of cases, with no serious adverse events.

[5]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41010772

SYSTEMATIC REVIEWS & META-ANALYSES — KNEE OA

Park et al. (2025) — Meta-Analysis: MFAT vs. PRP for Knee OA (RCTs Only)

This meta-analysis of 6 randomized controlled trials found that both MFAT and PRP provided clinically meaningful pain relief and functional improvement for up to 24 months, with MFAT showing a small but statistically significant advantage over PRP at the 6-month mark. Both treatments were equally safe, supporting MFAT as a viable alternative to PRP for knee arthritis.

[6]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/40990578

Hohmann et al. (2025) — Systematic Review of 21 Studies: MFAT for Knee OA

This comprehensive systematic review of 21 clinical studies found that MFAT injections consistently improved pain scores (from 5.2 to 3.2 on VAS) and all KOOS subscores at 6 and 12 months, demonstrating comparable effectiveness to other orthobiologic injections including PRP and BMAC. The review confirms MFAT is effective but notes that moderate study quality warrants cautious interpretation.

[7]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38467171

Hohmann et al. (2025) — Meta-Analysis: MFAT vs. PRP and BMAC for Knee OA

This meta-analysis directly comparing MFAT to PRP and BMAC found no statistically significant differences in pain or function scores at 3, 6, or 12 months, confirming that MFAT performs comparably to other orthobiologic treatments for knee arthritis. The findings suggest that the choice between MFAT, PRP, and BMAC may come down to practical considerations such as availability and patient preference rather than clinical superiority.

[8]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39751667

Batista et al. (2026) — Systematic Review of 19 RCTs: Adipose-Derived Cell Therapies for Knee OA

This systematic review of 19 randomized controlled trials found that all adipose-derived therapies (including MFAT) are safe and provide meaningful pain relief and functional improvement, with no serious treatment-related adverse events reported across any study. MFAT trials showed symptomatic benefits comparable to established injectable therapies, though structural cartilage changes on MRI were limited.

[9]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/42100287

HIP OSTEOARTHRITIS

Natali et al. (2023) — 3-Year Follow-Up: MFAT for Hip OA

This study of 55 patients with early-to-moderate hip arthritis found that over half (51%) experienced lasting benefit from a single MFAT injection with no need for further treatment at 3 years, while those who did eventually need surgery were able to delay hip replacement by an average of 16 months. The best results were seen in patients with mild-to-moderate disease (Oxford Hip Score 30–48), identifying the ideal candidates for this treatment.

[10]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36302901

Heidari et al. (2022) — MFAT vs. MFAT + PRP for Hip OA (147 Patients)

This observational study of 147 patients with hip arthritis (grades 1–4) found that both MFAT alone and MFAT combined with PRP produced significant improvements in pain and hip function scores, with over 60% of patients achieving a pain reduction of 20 points or more on the VAS scale. The combination of MFAT + PRP may be particularly useful for patients with low body fat where obtaining sufficient MFAT alone is challenging.

[11]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35207329

ROTATOR CUFF

Randelli et al. (2022) — Level II RCT: MFAT Augmentation of Arthroscopic Rotator Cuff Repair

This randomized controlled trial of 44 patients found that adding MFAT injection during arthroscopic rotator cuff surgery led to significantly better shoulder function scores (Constant-Murley) at 6 months compared to surgery alone, with no increase in complications or retear rates. The study was the first RCT to demonstrate that MFAT is a safe and effective addition to rotator cuff repair surgery.

[12]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35302901

Lundeen et al. (2023) — Adipose-Derived Cells vs. Corticosteroid for Partial Rotator Cuff Tears (3+ Year Follow-Up)

This long-term follow-up study found that patients with partial rotator cuff tears who received a single injection of adipose-derived regenerative cells had significantly better shoulder function scores (ASES) than those who received a corticosteroid injection, with benefits sustained beyond 3 years. MRI imaging at 6 months showed visible evidence of the cells actively promoting tissue healing, and no safety concerns were identified.

[13]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37935850

Ferrell et al. (2023) — Case Report: MFAT for Full-Thickness Supraspinatus Tear

A 70-year-old woman with a full-thickness rotator cuff tear that had not improved with conservative treatment received an MFAT injection and experienced progressive improvements in pain and function, with both ultrasound and MRI showing evidence of tendon healing over time. This case demonstrates that MFAT may offer a non-surgical option for certain non-retracted, full-thickness rotator cuff tears.

[14]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37727974

Hogaboom et al. (2021) — Pilot Study: MFAT for Refractory Rotator Cuff Disease in Wheelchair Users

This pilot study of 10 wheelchair users with chronic spinal cord injuries and shoulder pain from rotator cuff disease found that ultrasound-guided MFAT injections produced significant improvements in pain and function lasting through 12 months, with nearly 78% of patients achieving clinically meaningful pain reduction. The study highlights MFAT as a potentially valuable option for patients with limited surgical alternatives.

[15]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33830898

TENDINOPATHY & TENDON TEARS

Usuelli et al. (2018) — Level I RCT: Adipose SVF vs. PRP for Achilles Tendinopathy

This randomized controlled trial of 44 patients found that both adipose-derived stromal vascular fraction (SVF) and PRP injections significantly improved pain and function in chronic Achilles tendon problems, but patients receiving SVF recovered significantly faster in the first month. The study suggests adipose-derived treatment may be preferred for patients who need an earlier return to daily activities or sport.

[16]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/28251260

Iuso et al. (2022) — Case Report: MFAT for Intrasubstance Achilles Tendon Tear

A patient with a chronic partial Achilles tendon tear that had failed all other treatments received an MFAT injection and was able to return to full activity within 4 weeks, remaining completely pain-free at 6 months with ultrasound confirmation of progressive tendon healing. This case highlights the potential of MFAT as a regenerative treatment for partial Achilles tendon tears that have not responded to conventional therapy.

[17]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36068962

Siddiqui et al. (2024) — Case Report: MFAT for Full-Thickness Common Extensor Tendon Tear (Tennis Elbow)

A 56-year-old man with a full-thickness tear and retraction of his common extensor tendon (severe tennis elbow) — caused by a prior corticosteroid injection — received an MFAT injection and showed complete tendon bridging and remodeling on ultrasound by 15 weeks, with full resolution of the retraction. This case presents a promising non-surgical option for patients with full-thickness tendon tears who wish to avoid or cannot undergo surgery.

[18]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39387455

COMPREHENSIVE REVIEWS & SAFETY

Parmar et al. (2026) — Comprehensive Review: MFAT in Orthopedic Regeneration

This comprehensive narrative review found that MFAT (most commonly processed via the Lipogems system) has demonstrated consistent improvements in pain and function across multiple joint conditions, with a favorable safety profile and procedural simplicity that makes it an attractive point-of-care orthobiologic. The review notes that MFAT performs comparably to PRP and BMAC rather than showing clear superiority, and calls for larger, standardized trials to define its long-term role.

[19]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41862417

Varone et al. (2024) — Safety Study: MFAT Harvesting and Injection Under Local Anesthesia

This safety-focused case series of 34 patients confirmed that harvesting adipose tissue from the abdomen and injecting MFAT into the knee can be safely performed under local anesthesia alone (without sedation), with only minor bruising (77%) and mild temporary discomfort at the harvest and injection sites — and no major adverse events. The study supports MFAT as a safe, office-based procedure that does not require general anesthesia.

[20]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39631149

Zhao et al. (2021) — Network Meta-Analysis: Adipose MSCs, PRP, BMAC, and HA for Knee OA

This large network meta-analysis of 43 randomized controlled trials found that adipose-derived mesenchymal stem cells provided the best pain relief at both 6 and 12 months compared to PRP, BMAC, hyaluronic acid, and placebo, and were the only treatment to show significant pain improvement over placebo at 1 year. The study positions adipose-derived therapies as among the most effective biologic options for knee arthritis pain.

[21]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33713757

Clinical Guidance & Regulatory Standards

We follow the most rigorous standards for “minimal manipulation” and “homologous use” as outlined by the FDA. Our procedures are performed in-office using sterile, closed-system technologies to ensure patient safety and tissue integrity.

Research Integrity: We encourage patients to review these studies to better understand the biological basis for the therapies we offer. While this research is promising, it is important to discuss your specific imaging and symptoms with a specialist to determine your candidacy for treatment.